Targeting CSC-Specific Surface Markers

Identifying unique surface markers expressed by cancer stem cells (CSCs) is key to selectively targeting them without affecting normal stem cells. This track focuses on the discovery of CSC-specific markers such as CD44, CD133, and ALDH1. Researchers aim to develop targeted therapies, including monoclonal antibodies and small molecules, that can specifically recognize and eliminate CSCs. By utilizing these markers for drug delivery or immunotherapy, more precise and effective cancer treatments can be designed. The goal is to reduce tumor recurrence and improve treatment efficacy by targeting the CSC population while sparing healthy tissue, offering a promising approach to cancer therapy.

    Related Conference of Targeting CSC-Specific Surface Markers

    May 26-27, 2025

    15th World Congress on Breast Cancer

    Rome, Italy
    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    August 18-19, 2025

    6th Cancer Diagnostics & Treatment Conference

    Rome, Italy
    October 13-14, 2025

    8th International Conference on Anti-Cancer Drugs & Therapies

    Aix-en-Provence, France
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    October 22-23, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    October 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    Zurich, Switzerland
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain

    Targeting CSC-Specific Surface Markers Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in